The finding that CD14+HLA-DRlo/neg monocytes are detectable systemically in patients with a variety of malignancies and that they are functionally immune suppressive raises important questions regarding their influence in ex vivo DC vaccine preparations. This evidence concerns the gene CD14 and cancer.